Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Skye Bioscience, Inc. (SKYE)

NCM · Biotechnology

$0.61-0.01 (-1.27%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$21.6M
P/E (TTM)
EPS
$-1.43
Div Yield
52W Range
$0.57–$4.99
Beta
2.94

Company overview

Next earnings: 2026-08-06(9d)

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Peers in Biotechnology

All in industry →

Recent press releases

April 2026

3 months agoPREM14AHealthcare

Skye Bioscience, Inc. — PREM14A Filing

SKYESkye Bioscience, Inc.

# 🧾 What This Document Is This is a **preliminary proxy statement (PRE14A)** for Skye Bioscience. Think of it as an invitation and information packet for the company's annual shareholder meeting. Its main job is to ask shareholders to vote on key proposals, like electing directors and approving com

Read summaryView on SEC EDGAR
3 months agoPRE 14AHealthcare

Skye Bioscience, Inc. — PRE 14A Filing

SKYESkye Bioscience, Inc.

Here's a clear breakdown of Skye Bioscience's PRE 14A filing: # 🧾 What This Document Is This is a **preliminary proxy statement** for Skye Bioscience's 2026 Annual Shareholder Meeting. It outlines proposals shareholders will vote on and provides essential company information. Think of it as the ag

Read summaryView on SEC EDGAR
3 months ago8-KHealthcare

Skye Bioscience, Inc. — 8-K Filing

SKYESkye Bioscience, Inc.

# 🧾 What This Document Is This is an **8-K filing**, which is a report public companies file with the SEC to announce major events that shareholders should know about. In this case, Skye Bioscience is reporting that it has entered into a **Master Services Agreement** with a consulting firm called *

Read summaryView on SEC EDGAR

SEC filings

All filings →
3 recent filings shown in the timeline above. View all SEC filings →

Skye Bioscience, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
9,681,763 sh0.0%
2,007,704 sh0.0%
93,407 sh-92.7%
1,450,638 sh0.0%
882,785 sh0.0%
478,928 sh0.0%
380,478 sh-14.5%
281,841 sh+0.7%

People at Skye Bioscience, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$11.1M
06/25
NI -$17.6M
09/25
NI -$12.8M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.32
Prior: $-0.44
Revenue sparkline